Analyst picks & changes

Amgen Inc.

(AMGN)

David Stone of Cowen & Co. reiterated a "strong buy" after ABTI's Betafectin results came under fire primarily because of the study design.

Read the full 261 word article

How to gain access

Continue reading with a
two-week free trial.